Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence

Next Previous
Trial Profile

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 238
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 04 Dec 2024 Status changed from active, no longer recruiting to completed.
  • 07 May 2024 Results comparing outcomes from CheckMate 238 with those from the real-world Flatiron Health electronic health record, published in the Cancer Immunology Immunotherapy
  • 24 Oct 2023 7 years updated results presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top